Dr. Bream posted this critique of the FDA on his Bream

New Post Public Reply Private Reply Replies (2) Message Board
Enjay
2,427
Dr. Bream posted this critique of the FDA on his Bream Medical Facebook page yesterday.
I admire him for taking on the FDA in such a public and dramatic way, especially since he is a physician who presumably has nothing at stake other than the health of patients.


All of these countries look to the FDA for guidance for therapeutics. Our FDA has let them down.
I’ll say it again....the FDA’s cozy relationship with Big Pharma, whose drugs have all been failures in really sick COVID patients (sans Roche’s tocilizumab), has cost millions of lives worldwide.
Because all the Big Pharma companies failed, the FDA basically did nothing. Dr. Woodcock herself admitted all of the trials on actually sick patients were underpowered (the FDA signs off on trial design) when she participated in a forum with AMA President, Susan Bailey. As such, none of them were powered to hit a primary endpoint. So, basically, the therapeutic trials were a waste - UNLESS the FDA actually starts following the “safe and may be effective” criteria for an EUA. Then, other countries, who are struggling BADLY right now, can get medications like leronlimab, aviptadil, abs tocilizumab (although they have manufacturing shortfall). The FDA could also do an Operation Warp Speed for therapeutics as well!
How many people have to die for a p-value, Dr. Woodock?

So, let’s analyze the FDA’s record on COVID:

HCQ - failed EUA that was granted despite the data suggesting its failure

Plasma - failed EUA granted without any significant study showing benefit; only that if plasma is given sooner it any be more beneficial. But, at no time was a placebo-controlled trial done for its EUA. Those trials failed.

Remdesivir - failed EUA despite studies in China showing no benefit. Association with NIAID and Gilead got the goal posts moved on its study. It showed no benefit in severely ill patients and its 4 day reduction in hospitalization length didn’t hold up in larger trials.

Regeneron/Lily MABs - I told this page’s followers back in November these drugs would fail due to mutations in my talk about why leronlimab was better than bamlanivimab. And, guess what? States are now not using those drugs because the mutations rendered them useless. This will be another pretty much failed EUA. While these drugs had initial promise, much like with the vaccines, EUA without logistics made them hard to obtain. This would compounded by the need for an infusion in an overwhelmed healthcare system (which was another colossal US healthcare failure).

Baricitinib? (laughing emoji here)

As a physician, and as a human who has had a friend to die and a close friend lose his dad, what the FDA has done is indefensible, unethical, and a violation of the Hipppcratic Oath. When promising drugs have shown they’re safe, not allowing them to be used by the FDA is a violation of “first do no harm.”
It’s past time we demand better from our government. We have let the world down!
USFDA

CytoDyn Inc (CYDY) Stock Research Links

CYDY Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Rain Agent Vaults: Revolutionizing Payments with AI

Updated Category News Views 123

Innovative Payments with AI Power Alright, folks, Rain's gone and done something that's probably going to shake things up in the payments world—'cause they've given AI agents the ability to handle money like never before. We're not just talking about some run-of-the-mill integration here. This is a genuine game changer, promising to make agents as financially savvy as...

Continue Reading
ProBio, AbTis Forge Bond for Next-Gen Oncology ADCs

Updated Category News Views 99

Deal or No Deal: ProBio's New Licensing Agreement In the ever-evolving realm of biopharmaceuticals, ProBio's recent handshake with South Korea's AbTis is stirring the pot. The shot-callers at ProBio are passing the baton to AbTis, giving them a crack at developing a thumping new therapeutic antibody asset aimed squarely at oncology targets. Pretty slick move if you ask...

Continue Reading
Alogent's Unify Snags Award for Innovation and Impact

Updated Category News Views 104

Innovation That Captures Attention Alogent sure did grab the spotlight with their Unify platform walking away with a Credit Union Times Luminaries Award. The name of the game here is deposit processing innovation—the kind of buzz that turns heads in the banking world. This recognition isn't just another plaque for the lobby; it's a testament to a significant stamp on...

Continue Reading
Sokolove Law Wins $28.8M Verdict for Misdiagnosis Case

Updated Category News Views 122

Jury Awards $28.8 Million in Misdiagnosis Case Well, here's a tale that's bound to ruffle some feathers in the medical community—$28.8 million tossed on the table because an emergency room missed a life-threatening aortic aneurysm. For the uninitiated, this isn't just chump change; it's the cost of dropping the ball when the stakes are as high as a human life. A jury in...

Continue Reading
FirstDigital Expands Fiber Network in Utah and Arizona

Updated Category News Views 86

Weaving a Web of Connectivity Let's talk about FirstDigital putting its shoulder to the wheel in Utah and Arizona. They're expanding their redundant fiber network to rope in more businesses under their umbrella of connectivity. This ain't just another dry IT endeavor—it's about building a safety net for our ever-connected world. The Stakes of Network Disruption You know...

Continue Reading
Jubilant Eyes MPN Breakthrough with JBI-802 Data at ASH

Updated Category News Views 73

Presenting the Case for JBI-802 From the bustling circus of drug development, here comes Jubilant Therapeutics, strutting their stuff with JBI-802, a dual inhibitor designed to tackle myeloproliferative neoplasms (MPNs) with a one-two punch. Now, they're set to drop some spicy deets at the 68th ASH Annual Meeting in New Orleans this December. So what's the fuss about?...

Continue Reading
Alyssa Bunch: Big Moves in Tennessee Real Estate

Updated Category News Views 104

Navigating the Tennessee Real Estate Maze If you're talking about where the real estate action happens in Tennessee, you'd better mention Alyssa Bunch, the Vanderbilt-educated dynamo who turns the unforsale into the must-buy. Most of the deals she orchestrates are invisible to the public eye until they're all but written in ink and ready to reshape landscapes—or, more...

Continue Reading
Bakersfield Sees Spike in Crashes Post Time Change

Updated Category News Views 83

Evening Darkness and Safety Concerns Folks, it seems Bakersfield streets transform into a battlefield once the clock falls back. With darkness creeping in earlier, those evening hours right after the time change see a sobering uptick in accidents. According to an analysis by Chain | Cohn | Clark, pedestrian and bicyclist crashes from 5 to 7 p.m. double. It's not just...

Continue Reading
IASO Bio's In Vivo CAR-T: A Game Changer for Oncology?

Updated Category News Views 5

You ever feel like you're watching history happen right in front of you? That's the vibe with IASO Bio's latest move in the realm of oncology. This outfit just scored a major victory, getting China's NMPA and the U.S. FDA to greenlight their IASO208, a CD20-targeting in vivo CAR-T therapy. It's not every day you see a company land dual regulatory nods like...

Continue Reading
Zephyr's Alto Hood: Redefining Kitchen Versatility

Updated Category News Views 75

An Artist in the Kitchen Who knew a kitchen hood could be a canvas, right? Zephyr, always a punch above the ordinary in kitchen design, has pulled another rabbit out of their hat with the Alto Wall Custom Hood. Forget blending in; this piece is about standing out and shouting style—all while keeping your cooking area fresh. Options Galore The Alto Hood isn't about...

Continue Reading

Top 5 Most Recently Viewed Articles

Constellation Brands Schedules Earnings Call for Q2 2026

Updated Category News Views 395

Constellation Brands Sets New Reporting Date Constellation Brands, Inc. (NYSE: STZ), a prominent player in the beverage alcohol sector, has recently revised its reporting schedule for the financial results of its second quarter, which ended on August 31, 2025. The new reporting date is set for October 6, 2025, after the markets close. Investors and analysts will be able...

Continue Reading
Bullish Trends Continue for Charter Communications in Options Market

Updated Category News Views 212

Analyzing the Recent Options Trends of Charter Communications The options market is bustling with activity around Charter Communications, indicating a strong bullish sentiment. Investors with significant capital are positioning themselves favorably, potentially anticipating upward price movements for the stock, CHTR. Summary of Options Trading Activity Examining the...

Continue Reading
California Water Service Group's Insights on Sustainability Efforts

Updated Category News Views 386

California Water Service Group Advances Sustainability Initiatives In its latest report, California Water Service Group (NYSE: CWT) has unveiled significant progress on various sustainability efforts aimed at minimizing its environmental footprint and enhancing corporate responsibility. This comprehensive overview showcases the Group's dedication to maintaining high...

Continue Reading
Deadline Approaches for Outset Medical Class Action Investors

Updated Category News Views 50

Important Deadline for Outset Medical Investors Investors, it’s time to stay alert! There’s an upcoming deadline that you need to be aware of regarding the class action lawsuit against Outset Medical, Inc. This lawsuit concerns investors who purchased or acquired securities of Outset Medical during a specific period. With the deadline looming, many individuals may be...

Continue Reading
Investors Losing from ASML Holding N.V. Should Seek Justice

Updated Category News Views 145

Investors' Alert: Class Action Against ASML Holding N.V. ASML Holding N.V. (NASDAQ: ASML) is currently facing a class action securities lawsuit that aims to defend the interests of its investors who may have suffered financial losses. This legal move is significant, especially for those who have been adversely affected by certain events within the semiconductor industry....

Continue Reading